Transformation to small cell lung cancer and activation of KRAS during long-term erlotinib maintenance in a patient with non-small cell lung cancer: A case report

Epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (non-SCLC) benefits from first-line treatment with first generation tyrosine kinase inhibitors (TKIs). However, drug resistance is inevitable through different mechanisms and is dominated by the acquisition of the T790M muta...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Lett
Hlavní autoři: Gu, Yangchun, Zhu, Xiang, Cao, Baoshan, Wu, Xue, Tong, Xiaoling, Shao, Yang W., Liang, Li
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2019
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507320/
https://ncbi.nlm.nih.gov/pubmed/31186738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10196
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky